Marker Therapeutics Awarded $2.6M FDA Grant to Advance Pancreatic Cancer Therapy

Marker Therapeutics announced it has been awarded a $2.6 million grant from the U.S. Food and Drug Administration (FDA) under its Orphan Products development program. The non-dilutive funding will support a Phase 1 clinical study of the company's lead investigational MAR-T cell therapy, MT-601, for patients with locally advanced unresectable pancreatic cancer.

Key Details

• Grant: $2.6 million from the FDA’s Orphan Products Clinical Trials grants program, a highly competitive initiative that selected six projects from 66 applications in fiscal year 2026.
• Purpose: To advance the clinical development of MT-601, a multi-antigen recognizing T cell therapy, specifically for pancreatic cancer.
• Timeline: The company expects to initiate the clinical study in the first quarter of 2027.